Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 14/20 | 0.51 |
| ▸ | EDNRB | P24530 | 12/20 | 0.51 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8626015 | 0.91 | EDNRA (0.53) | EDNRAEDNRB | |
| SCHEMBL7945230 | 0.90 | PRKCI (0.48) | EDNRAEDNRBPRKCIPRKCZCYP19A1 | |
| SCHEMBL7534309 | 0.88 | EDNRA (0.55) | EDNRAEDNRBSCN9A | |
| SCHEMBL8620432 | 0.86 | EDNRA (0.51) | EDNRAEDNRBPRKCIPRKCZCYP19A1 | |
| SCHEMBL8623907 | 0.85 | PRKCI (0.46) | EDNRAEDNRBPRKCIPRKCZCYP19A1 | |
| SCHEMBL8622696 | 0.85 | SCN9A (0.44) | EDNRAPRKCIPRKCZCYP19A1SCN9A | |
| SCHEMBL7538071 | 0.79 | EDNRA (0.54) | EDNRAEDNRB | |
| SCHEMBL8622873 | 0.79 | EDNRA (0.53) | EDNRAEDNRBCTNNB1WNT3A | |
| SCHEMBL3571615 | 0.79 | PPARG (0.53) | — | |
| SCHEMBL7534451 | 0.75 | EDNRA (0.48) | EDNRAEDNRBSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5817693-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 1998-10-06 | — | — | US | disclosed |
| US-5719182-A | TREATING HYPERTENSION, RENAL FAILURE, CEREBROVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |